Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin and paclitaxel in patients with advanced cancer

(2010) G J Rustin et al.   BRITISH JOURNAL OF CANCER

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

(2009) R Sharma et al.   BRITISH JOURNAL OF CANCER

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

(2009) I. Vergote et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

Antiangiogenic drugs in ovarian cancer

(2008) G C Kumaran et al.   BRITISH JOURNAL OF CANCER

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

(2008) Gabriella Ferrandina et al.   JOURNAL OF CLINICAL ONCOLOGY